QL-415 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QL-415’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QL-415 is under development for the treatment of advanced, recurrent, metastatic solid tumors. It is administered through intravenous route and acts by targeting PD-L1 and IL-15.
For a complete picture of QL-415’s drug-specific PTSR and LoA scores, buy the report here.